TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1.Confirmed diagnosed steroid-resistant aGVHD after allo-HSCT. 2. Neutrophile granulocyte (ANC) ≥ 0.5 x 10\^9/L. 3. Creatinine below 2 times normal upper limit . 4. Willing and able to sign written informed consent.~Exclusion Criteria:~- 1. Untoleratation of the treatment. 2. Primary disease are not effectively controlled or are progressing. 3. Active infection (Bacteria, fungi, viruses ). 4. Combined with dysfunction of multiple organ. 5. Female patients who are nursing or pregnant, or who contemplate pregnancy during the study period.~6. Patients who are deemed unsuitable for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- UC-MSC and anti-CD25 mAb (Type: EXPERIMENTAL): UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.
- Anti-CD25 mAb (Type: ACTIVE_COMPARATOR): Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hot Flashes on Sleep and Mood Disturbance

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18-45 years old~* Premenopausal~* Willingness to use barrier methods of contraception during study and after completion of study until menses resume~* Good general health~Exclusion Criteria:~* Pregnancy or currently breastfeeding~* Hot flushes~* Mid-luteal phase progesterone \<3ng/mL~* Clinically significant abnormalities in screening blood tests~* BMI \> 35 kg/m2~* Previously diagnosed osteoporosis or osteopenia~* Clinically significant depressive symptoms~* Psychiatric illness~* Sleep apnea or periodic limb movement of sleep (PLMS)~* Contraindication, hypersensitivity, or previous allergic reaction to GnRH agonists~* Current or recent use of centrally active medications~* Current or recent use of systemic hormone medications~* Night shift workers~* Current use of over-the-counter (OTC) medications that may affect hot flashes, sleep, or mood~* Abnormal vaginal bleeding~* History of any medical diseases that may put subject at risk when treated with study medication.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- GnRH Agonist Injection (Type: EXPERIMENTAL): We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inpatients, who received IV treatment (bolus administration) with cafedrine/theodrenaline or ephedrine (Ephedrin Meduna) due to an acute arterial hypotension~* Consent to use of data is available~* Patient under careful blood pressure and pulse monitoring (at least 2 minutes measuring interval (BP/HR) and/or at least 7 measurements within the first 15 minutes after the first application of cafedrine/theodrenaline or ephedrine)~Cohort A:~* Treatment of hypotension in \< 100 mm Hg syst. and/or drop in blood pressure \> 20% syst. compared to preoperative base value (syst.)~* Patients ≥ 50 years old~* Pre-existing comorbidities (ASA classification 2-4)~* Elective surgery~* General anaesthesia with propofol/fentanyl ≥ 0.2 mg (or equivalent)~Cohort B:~* Treatment of hypotension in \< 100 mm Hg syst. and/or drop in blood pressure \> 10% syst. compared to preoperative base value (syst.)~* Patients ≥ 18 years old~* Caesarean section under spinal anaesthesia~Exclusion Criteria:~* Contraindication to the use of cafedrine/theodrenaline or ephedrine (Ephedrin Meduna) in accordance with current German specialist information~  * Hypersensitivity to any product ingredient~ * Hypertensive blood pressure readings~ * Mitral stenosis~ * Narrow-angle glaucoma~ * Hyperthyroidism~ * Pheochromocytoma~ * Prostatic adenoma with urinary retention~ * Bronchial asthmatics with sulphite sensitivity~ * Hyper-excitability~ * Arteriosclerosis~ * Aneurysm~ * Treatment with other indirect sympathomimetic drugs (Example: phenylpropanolamine, phenylephrine, pseudoephedrine or methylphenidate)~ * Use of Monoamine oxidase (MAO) inhibitors (including within the last two weeks)~* Prophylactic administration of cafedrine/theodrenaline or ephedrine or other anti-hypertensives~* Sepsis, septic shock or systemic inflammatory response syndrome (SIRS)~Cohort A:~• Intra-cranial surgery or heart surgery~Cohort B:~* High-risk pregnancy (emergency Caesarean, severe infantile malformation)~* Multiple pregnancy~* Amniotic infection syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): Patients ≥ 50 years old, with pre-existing comorbidities, who receive general anaesthesia
- Cohort B (Type: None): Patients, who undergo caesarean section under spinal anaesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glargine Versus NPH in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus and chronic kidney disease secondary to diabetic nephropathy in stages 3 and 4 (moderate and severe nephropathy, corresponding to glomerular filtration rate of 15-59 ml/min/1.73m²) will be included in the study.~Exclusion Criteria:~* Patients with systemic neoplasias,~* HIV, chronic kidney disease or nephropathy from other etiologies,~* severe psychiatric disorders~* pregnant women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glargine insulin (Type: EXPERIMENTAL): This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
- NPH insulin (Type: ACTIVE_COMPARATOR): This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coping Skills Training for Adolescents With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of JPFS based upon widespread pain for over 3 months, at least 5 tender points, and associated features such as sleep difficulty, fatigue, and abdominal discomfort~* Average pain intensity greater than 4 on the Visual Analog Scale~* Functional disability score greater than 7~* Stable medications for 8 weeks prior to study entry~Exclusion Criteria:~* Other chronic rheumatic diseases, such as juvenile rheumatoid arthritis or lupus~* Significant developmental delay or impairments, such as autism, cerebral palsy, or mental retardation~* Present or lifetime psychiatric diagnosis that meets DSM-IV criteria for panic disorder, bipolar disorder, major depressive disorder, or psychosis~* Opioid medications are disallowed when used on an ongoing basis for treatment of fibromyalgia pain

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Coping Skills (Type: EXPERIMENTAL): Patients will receive 8 weeks of behavioral training in pain coping strategies
- Education (Type: ACTIVE_COMPARATOR): Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Paricalcitol in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older.~* First or second deceased donor or living donor renal transplant.~* Normocalcemia or hypocalcemia.~* Willing to give informed consent~Exclusion Criteria:~* Third or subsequent renal transplant.~* Incompatible blood type or positive cross-match donor.~* Multiple organ transplant recipients.~* Diabetic with plans for future pancreas or islet transplant.~* Evidence of donor-specific sensitization (positive T-cell and/or B-cell flow cytometric cross-match).~* Documented hypercalcemia (total serum calcium 10.5 mg/dl on two separate occasions) prior to transplantation.~* Serum 25(OH)vitamin D concentration ≤ 10 ng/ml

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immunosuppression without paricalcitol (control) (Type: OTHER): Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
- Immunosuppression with paricalcitol (Type: ACTIVE_COMPARATOR): Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buffered Local Anesthetic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children or children with mild controlled systemic illness~* Treatment planned to receive restorative work on both sides of mouth (left vs right) under deep sedation, requiring local anesthetic administration~Exclusion Criteria:~* Children present with any illness or symptoms that can alter pain perception such as pain in head and neck area due to TMJ disorders, arthritis, autoimmune diseases~* Antibiotic premedication requirement~* History of taking medications (NSAIDs, narcotics, sedatives, and antianxiety or antidepressant medications) that may affect anesthetic assessment~* Has signs of dental pain, odontogenic abscess or facial cellulitis~* Allergy to local anesthetics or sulfites

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Buffered Anesthetic Side/Non-buffered Anesthetic Side (Type: EXPERIMENTAL): Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic.~Patients will be randomized to one side of the mouth getting the buffered anesthetic and the other side of the mouth to the non-buffered anesthetic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Each subject may be of either sex and of any race/ethnicity, and must be \>=6 and \<=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of \>159mg/dL~* Each subject's parent/guardian must be willing to give written informed consent on his/her behalf.~Exclusion Criteria:~Each subject must not:~* Have known hypersensitivity or any contraindication to ezetimibe.~* Have use of any investigational drugs within 30 days of study entry.~* Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.~* Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing~* Have known congenital cardiac disorder.~* Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).~* Be known to be human immunodeficiency virus (HIV) positive.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Type: EXPERIMENTAL): Ezetimibe 10-mg tablet once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 18 and 75 years and referred to capsule endoscopy because of suspected small-bowel disease are prospectively eligible for entry into the study.~Exclusion Criteria:~* Age \< 18 or \> 75 years~* Known or suspected GI stricture or fistula~* A history of GI tract resection~* Swallowing disorders~* Intensive therapy with fasting and parenteral nutrition;with a disease that may reduce movement of the GI tract, such as diabetes mellitus~* Medications that could affect gastrointestinal movement within one week~* Implanted with a medical electronic device~* Active inflammatory bowel disease, toxic megacolon, toxic colitis~* Severe pulmonary, cardiac, renal, or hepatic disease~* Uncontrolled hypertension (systolic blood pressure\>170 mm Hg, diastolic blood pressure\>100 mm Hg);~* Disturbance of electrolytes~* Pregnancy or lactation~* Patients inability to provide written voluntary informed consent~* Participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
- Group B (Type: ACTIVE_COMPARATOR): the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
- Group C (Type: ACTIVE_COMPARATOR): the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
- Group D (Type: ACTIVE_COMPARATOR): Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
- Group E (Type: ACTIVE_COMPARATOR): Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A liver biopsy required within 3 years prior to screening unless the patient has a contraindication for a liver biopsy~* Patients with bridging fibrosis or cirrhosis and without a liver biopsy result within 2 years prior screening must have an ultrasound taken within 2 months prior to the screening visit or during screening with no findings suspicious for hepatocellular carcinoma (HCC)~* Genotype-1 hepatitis C virus (HCV) infection~* Plasma HCV ribonucleic acid (RNA) of more than 10,000 IU per mL~* Documented human immunodeficiency virus-type 1 (HIV-1) infection at least 6 months prior to screening~Exclusion Criteria:~* Patient showing evidence of hepatic decompensation (ie, history or current evidence of ascites, bleeding varices or hepatic encephalopathy, albumin serum concentration less than 3.3 gm per dL, prolonged prothrombin time \[PT\] expressed as international normalized ratio \[INR\] more than 1.5)~* Any liver disease of non-HCV etiology~* Co-infection with hepatitis B virus (hepatitis B surface antigen \[HBsAg\] positive)~* An acute HIV-1 infection; or HIV-2 infection~* Change in antiretroviral (ARV) regimen within the last 4 weeks prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 + pegylated interferon alpha-2a + ribavirin (Type: EXPERIMENTAL): Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epicardial Ablation in Brugada Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients affected by Brugada Syndrome, profiled by genetic testing, with documented spontaneous or drug-induced type I BrS ECG pattern, with symptoms attributable to ventricular arrhythmias and presenting multiple documented arrhythmic episodes~* Patients with an ICD already implanted~* Patients referred to the center for an electrophysiological study and indication to a potential concomitant radio-frequency catheter ablation (RFA) of ventricular arrhythmia or ventricular fibrillation~* Age ≥ 18~* Willingness to attend follow-up examinations~* Written informed consent to the participation in the trial~Exclusion Criteria:~* Pregnancy or breast-feeding~* Patients with low arrhythmic risk (Brugada pattern III)~* Life expectancy \< 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mapping/ablation (Type: EXPERIMENTAL): Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (\> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete